Genesis Healthcare

What Genesis Healthcare does

Genesis Healthcare, now operating as A.D.A.M. Innovations Co. following a November 1, 2025 rebrand, is a Japan-headquartered genomics and precision health company that combines genetic sequencing with AI-driven prediction models. Founded in 2003 and headquartered in Tokyo's Ebisu district, the company runs a CAP-accredited, Japanese CLIA-registered laboratory (Genesis Institute of Genetic Research, or GIGR) equipped with next-generation sequencing, microarray, PCR, and whole genome sequencing platforms supported by robotics and automation. It has processed over 2.9 million genetic tests and holds 74 patents on AI prediction models. The portfolio is organized across three core lines plus adjacent platforms: GenesisGaia, a population genomic research platform that gives pharmaceutical, life sciences, beauty, health, and food companies AI-powered access to Japanese genomic and phenotypic data; GenesisPro and GIGR, providing clinical genetic testing and bioinformatics to medical institutions; and GeneLife, a direct-to-consumer brand selling at-home DNA kits spanning health, personality, diet, beauty, sports, fitness, and ancestry. Supporting products include GeneLink (an AI-driven ad-tech platform that targets consumers using genetic predispositions), GeneLock (a genetic data protection platform), GeneAI Forecast (15 predictive health models), and a COVID-19 PCR testing service.

The company monetizes through four distinct streams: one-time unit-priced sales of DTC test kits via the GeneLife website, recurring B2B platform and clinical testing fees through GenesisGaia and GenesisPro, ad-tech revenue through GeneLink, and emerging personalized supplements tied to its JG Group-funded production program. Go-to-market is hybrid, combining direct-to-consumer e-commerce for GeneLife with enterprise field sales for pharmaceutical, healthcare, and beauty clients in Japan and a newly developed International Services Division. The company claims 74% DTC market share in Japan per Fuji Chimera Research Institute and operates as a privately held, bootstrapped Japanese corporation, though it has raised approximately $36.7M cumulatively from investors including Rakuten, Omron Healthcare, Founders Fund, Mitsui & Co, and most recently JG Group. Strategic direction in 2025-2026 emphasizes international expansion, a multi-year Oxford Nanopore rare disease genomics partnership, and a pivot toward AI-personalized consumer health products beyond testing.

Name

Genesis Healthcare

Legal name

Genesis Healthcare Co.

Website

https://genesis-healthcare.jp

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Genesis Healthcare (now A.D.A.M. Innovations Co.) is a Tokyo-based genomics and precision health company operating Asia's largest population genomic platform, offering AI-powered clinical testing, direct-to-consumer DNA kits, and ad-tech to pharmaceutical, healthcare, research, and consumer clients.

Ownership category

akta.pro rank

Product category

Genetic Testing and Genomic Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Genetic testing services
• Direct-to-consumer genomics
• Population genomic platform
• Clinical genetic diagnostics
• AI-driven precision health

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Direct-to-Consumer Genetic Testing: GeneLife brand sells at-home DNA test kits and personalized health reports directly to consumers. Revenue generated from test kit sales and premium wellness recommendations. Services leverage multiple sequencing technologies including PCR, microarray and Whole Genome Sequencing.
2. B2B Genomic Research Services: GenesisGaia platform provides pharmaceutical, life sciences, beauty and health companies access to genomic and phenotypic data for R&D purposes. GenesisPro offers clinical genetic testing services to medical institutions.
3. GeneLink Ad-Tech Services: AI-powered precision marketing platform enabling brands to target audiences based on genetic predispositions and lifestyle data.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Genesis Healthcare (now A.D.A.M. Innovations Co.) operates a genomics and precision health platform that sells direct-to-consumer at-home DNA test kits under the GeneLife brand, clinical genetic testing and screening services through its CAP-accredited Genesis Institute of Genetic Research (GIGR) laboratory (GenesisPro), population genomic research data access for pharmaceutical and life sciences companies via the GenesisGaia platform, and an AI-powered ad-tech service (GeneLink). The company combines Next Generation Sequencing, microarray, and PCR technologies with 74 patented AI prediction models to deliver genetic insights to both individual consumers and enterprise customers.

Product overview

A.D.A.M. Innovations (formerly Genesis Healthcare Co., renamed November 1, 2025) operates as a comprehensive genomics and precision health platform with a multi-product portfolio. The core offerings include GenesisPro (clinical genetic testing at CAP-accredited GIGR laboratory), GeneLife (direct-to-consumer genetic testing), and GenesisGaia (population genomic research platform). Supporting platforms include GeneLink (AI-powered ad-tech), GeneLock (genetic data protection), and Covid-19 PCR testing services. The company leverages next-generation sequencing, microarrays, and PCR technologies across its laboratory operations, with AI prediction models powering health analytics and personalized recommendations. With over 2.9 million genetic tests performed and 74% DTC market share in Japan, the company serves both B2B research/institutional clients and B2C consumer segments.

Differentiator

Problem solved

Functional benefit

Brands

• GenesisGaia: Asia's first and largest genomic platform servicing researchers in life sciences, pharmaceutical, beauty & health, food and product development to access genomic and phenotypic information for R&D needs
• GenesisPro
• GeneLife
• GeneLink
• GeneLock
• GeneAI Forecast

Products and services

• GenesisGaia Asia's first and largest population genomic platform that provides researchers in life sciences, pharmaceutical, beauty, health, food, and product development with access to genomic and phenotypic information for R&D needs. Powered by AI, advanced visualizations, screening tools, and prediction algorithms, it supports drug discovery, medical R&D, and service personalization.
• GenesisPro One-stop clinical genetic testing and screening services delivered at the CAP-accredited and Japanese CLIA-registered Genesis Institute of Genetic Research (GIGR) laboratory in Tokyo. Provides comprehensive services from sample preparation through testing and bioinformatics to medical professionals, researchers, and healthcare institutions at competitive cost across Japan and Asia.
• GeneLife Direct-to-consumer genetic testing brand offering at-home and non-invasive DNA tests covering health, personality, diet and nutrition, beauty and skincare, sports and fitness, and ancestry. Leverages PCR, microarray, and Whole Genome Sequencing (WGS) technologies to deliver personalized test reports and wellness recommendations to individual consumers.
• GeneLink AI-powered ad-tech platform that combines genetics, lifestyle data, and AI to enable precision marketing. Built on the largest genomic database of the Japanese population, it allows brand marketers to leverage biological predispositions for deeper audience personalization beyond traditional demographic or behavioral targeting.
• GeneLock World's first genetic data protection platform enabling secure management and protection of genetic data for individuals and organizations.
• COVID-19 PCR Testing At-home COVID-19 PCR testing service with saliva sample collection from home, including doctor consultation and smartphone-delivered results, analyzed under strict international and Japanese standards at the company's laboratory in Tokyo.
• GeneAI Forecast Predictive genetic analysis platform with 15 predictive models and enhanced lifestyle integration, providing health predictions and wellness recommendations by combining genetics, lifestyle data, and real-time information.

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Oxford Nanopore TechnologiescoreStrategic or Co-development Partner · 3 February 2026Multi-year partnership to launch a national rare disease genomics pilot in Japan in H2 2026. This collaboration is part of broader UK-Japan scientific cooperation to accelerate genomics research and clinical application, establishing nanopore sequencing technology in Japan's clinical workflows.
• Swiss Biotech AssociationminorStrategic or Co-development Partner · 4 November 2025Round table discussions at Swiss Biotech Day 2025 highlighting opportunities for Japanese-Swiss biotech collaboration. The event was organized by Swiss Biotech Association with participation from 15 Japanese companies.
• Swiss Business Hub JapanminorGTM or Marketing Partner · 4 November 2025Organized delegation of Japanese companies including Genesis Healthcare for Swiss Biotech Day 2025 to foster cross-border partnerships and position Switzerland as gateway for Japanese life science companies.
• Daiichi Sankyo Co., Ltd.minorStrategic or Co-development Partner · 4 November 2025Round table discussion participant at Swiss Biotech Day 2025 alongside Genesis Healthcare, highlighting opportunities for Japanese-Swiss biotech collaboration.
• NTT Precision MedicinecoreStrategic or Co-development PartnerA.D.A.M. Innovations enables pharmacogenomics services for NTT Precision Medicine, providing genetic analysis capabilities for precision medicine applications.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• 23andMe: Direct competitor in direct-to-consumer genetic testing for health, ancestry, and traits. Comparable in offering at-home DNA kits with personalized reports, but Genesis has stronger B2B platform depth and Asian-market focus.
• Prenetics (Circle DNA): Asia-based (Hong Kong) genetic testing company operating Circle DNA consumer brand. Closest geographic peer — both target Asian populations with DTC and clinical genomics, similar regulatory positioning, and competing for the same pharma data partnerships.
• MyHeritage: Direct competitor in DTC genetic testing with focus on ancestry and health. Offers consumer DNA kits with online portal; comparable product mix though Genesis has stronger clinical and B2B platform offerings.
• Helix: Genomic platform operating both a population genomics database and clinical applications. Highly comparable to GenesisGaia model — sequencing-as-a-service plus app ecosystem — and a likely model Genesis is emulating for its B2B platform strategy.
• Invitae: Clinical genetic testing company providing comprehensive medical genetic testing services to healthcare providers. Comparable in clinical diagnostics arm (GenesisPro/GIGR) but US-anchored rather than Asia-focused.
• Color Genomics: Genetic testing company offering clinical-grade health and ancestry testing with population genomics platform (research initiative for pharma). Comparable business model spanning DTC, clinical, and pharma data services.

Regional players

• Macrogen: Korea-based genomic services company providing sequencing, microarray, and clinical genetic testing for pharma and research. Comparable Asian competitor with similar B2B research services model and academic/pharma client base.
• MedGenome: India-headquartered genomic diagnostics and research services company serving pharma and clinicians. Comparable Asian emerging player in clinical genomics with similar B2B pharma services model.

Broad incumbents

• BGI Group: China-headquartered global genomics giant with sequencing services, clinical diagnostics, and population genomics programs (notably NIFTY). Comparable in scale of database and breadth of services; broader incumbent with stronger global footprint but different geographic anchor.

Emerging players

• Veritas Genetics: Whole genome sequencing provider offering DTC and clinical WGS services. Highly comparable to GeneLife WGS consumer offering; similar positioning around premium WGS-driven health insights.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/genesishealthca

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Healthcare